For research use only. Not for therapeutic Use.
(Rac)-Ruxolitinib-d8 (CAS: 1794791-38-0), a premium pharmaceutical research compound designed for advanced oncology and immunology studies. As a deuterated analog of Ruxolitinib, it offers enhanced stability and improved pharmacokinetic properties. (Rac)-Ruxolitinib-d8 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for myeloproliferative disorders and other immune-related conditions. Trusted by leading laboratories, (Rac)-Ruxolitinib-d8 is your go-to solution for cutting-edge cancer and immunology research. Unlock new possibilities in treatment with (Rac)-Ruxolitinib-d8, where innovation meets reliability.
| Catalog Number | S000192 |
| CAS Number | 1794791-38-0 |
| Molecular Formula | C17H10D8N6 |
| Purity | ≥95% |
| IUPAC Name | 3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile |
| InChI | InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/i1D2,2D2,3D2,4D2 |
| InChIKey | HFNKQEVNSGCOJV-SVYQBANQSA-N |
| SMILES | [2H]C1(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3)[2H] |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |
